Theranostic prostate cancer trial advances to cohort 3
Filed with ASX · · 5 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity Bolsters Antibody Pre-Targeting with IP from MSK
- Final Cohort opens for CL04 Paediatric Neuroblastoma trial
- Phase II SABRE prostate cancer trial reaches 50% recruitment
- Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
- Clarity Establishes US Center of Excellence for Research
Later from Clarity Pharmaceuticals
- First PC participant treated at the highest dose level
- First neuroblastoma participant treated in highest cohort
- BOP preliminary trial results presented at EANM 2023
- Company Presentation E&P Small Cap Healthcare Conference
- First patient treated with Cu-67 SAR-Bombesin
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals